Bill Few Associates’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.32M Sell
9,146
-65
-0.7% -$15.1K 0.49% 50
2026
Q1
$2.25M Hold
9,211
0.54% 48
2025
Q4
$1.91M Buy
9,211
+223
+2% +$44.1K 0.47% 54
2025
Q3
$1.67M Sell
8,988
-93
-1% -$15.9K 0.43% 54
2025
Q2
$1.39M Sell
9,081
-154
-2% -$23.7K 0.39% 58
2025
Q1
$1.53M Buy
9,235
+171
+2% +$26.8K 0.55% 51
2024
Q4
$1.31M Sell
9,064
-165
-2% -$25.6K 0.46% 54
2024
Q3
$1.5M Buy
9,229
+9
+0.1% +$1.43K 0.53% 50
2024
Q2
$1.35M Sell
9,220
-38
-0.4% -$5.65K 0.52% 50
2024
Q1
$1.46M Buy
9,258
+41
+0.4% +$6.53K 0.59% 46
2023
Q4
$1.44M Buy
9,217
+52
+0.6% +$7.97K 0.66% 40
2023
Q3
$1.43M Sell
9,165
-381
-4% -$62.9K 0.75% 35
2023
Q2
$1.58M Buy
9,546
+1,003
+12% +$162K 0.82% 34
2023
Q1
$1.32M Buy
8,543
+479
+6% +$77.3K 0.74% 36
2022
Q4
$1.42M Sell
8,064
-381
-5% -$65.8K 0.84% 34
2022
Q3
$1.38M Sell
8,445
-198
-2% -$33.5K 0.93% 32
2022
Q2
$1.53M Sell
8,643
-10
-0.1% -$1.78K 0.98% 32
2022
Q1
$1.53M Buy
8,653
+734
+9% +$125K 0.84% 33
2021
Q4
$1.35M Buy
+7,919
New +$1.3M 0.7% 34

Other funds holding JNJ

Bill Few Associates's JNJ Position: Q2 2026 in Review

Bill Few Associates reduced its Johnson & Johnson (JNJ) stake by 0.71% in Q2 2026, selling an estimated $15.1K and leaving 9,146 shares worth $2.32M. The position accounts for 0.49% of the portfolio, ranked #50.

Bill Few Associates first reported a position in JNJ in Q4 2021 and has held it in 19 quarters since. 899 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Bill Few Associates held 9,146 shares of Johnson & Johnson worth $2.32M as of Q2 2026.
  • Bill Few Associates sold 65 Johnson & Johnson shares in Q2 2026, an estimated $15.1K.
  • Johnson & Johnson made up 0.49% of Bill Few Associates's portfolio in Q2 2026, its #50 holding.
  • Bill Few Associates first reported a position in Johnson & Johnson in Q4 2021 and has held it in 19 quarters since.
  • 899 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Bill Few Associates's 13F filing for Q2 2026, filed 7 Jul 2026.